 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Theresa Medina and Sapna Patel.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.296 |
|
|
|
-
MacBeth ML, Bagby SM, Borgers JSW, Turner JA, Anderson K, Whitty PA, Hartman SJ, Yacob B, Rebecca VW, Davila E, Pitts TM, Medina TM, Patel SP, McCarter MD, Robinson WA, Tobin RP, Couts KL. Decitabine reverses innate immune gene suppression in rare melanomas. Mol Cancer Ther. 2026 Jul 14.
Score: 0.061
-
Borgers JSW, Wu CC, Medina TM, Muckle CM, Katsnelson EN, Whitty PA, Mantle L, Patel SP, Gao D, Jordan KR, Robinson WA, Tobin RP, Couts KL, McCarter MD. CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial. J Natl Compr Canc Netw. 2026 Mar 31; 24(3.5).
Score: 0.060
-
Borgers JSW, Wu CC, Medina TM, Muckle CM, Katsnelson EN, Whitty PA, Mantle L, Patel SP, Gao D, Jordan KR, Robinson WA, Tobin RP, Couts KL, McCarter MD. CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial. J Natl Compr Canc Netw. 2026 Mar 31; 24(3.5).
Score: 0.060
-
MacBeth ML, Bagby SM, Borgers JSW, Turner JA, Anderson KC, Whitty PA, Hartman S, Yacob B, Rebecca VW, Davila E, Pitts TM, Medina TM, Patel SP, McCarter MD, Robinson WA, Tobin RP, Couts KL. Decitabine reverses innate immune gene suppression in rare melanomas. bioRxiv. 2025 Aug 28.
Score: 0.058
-
Borgers JSW, Medina TM, Robinson WA, Couts KL, Katsnelson EN, Muckle CM, Davilla E, Patel SP, Gao D, Tobin RP, McCarter MD. Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update. Ther Adv Med Oncol. 2025; 17:17588359251349321.
Score: 0.057
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|